Abstract
Silybin and its congeners belong to a group of flavonolignans with strong biological activities. These compounds are potentially applicable in human medicine, e. g. due to their cytoprotective activity. As a part of herbal preparations available on the open market, they face the risk of potential negative drug-drug interactions. This review aims to evaluate current knowledge on the metabolism of these compounds by biotransformation enzymes, interactions with other drugs, their pharmacokinetics, and bioavailability. While silybin and its derivatives interact with cytochrome P450s, only metabolism of silybin by cytochrome P450 2C8 poses a risk of adverse effects. The main biotransformation route of silybin and derivatives was identified as conjugation, which is stereospecific in case of silybin. Studies of the metabolism, pharmacokinetics, potentional drug – drug interactions and increasing bioavailability of these flavonolignans play an important facet of possible therapeutical use of these compounds. The goal of our review is to aid future developments in the area of silybin research.
Keywords: Biotransformation, cytochrome P450, diastereoisomers, glucuronidation, silibinin, silybin, silymarin, sulfonation.
Current Drug Metabolism
Title:Biotransformation of Silybin and its Congeners
Volume: 14 Issue: 10
Author(s): Vladimír Kren, Petr Marhol, Katerina Purchartová, Eva Gabrielová and Martin Modriansky
Affiliation:
Keywords: Biotransformation, cytochrome P450, diastereoisomers, glucuronidation, silibinin, silybin, silymarin, sulfonation.
Abstract: Silybin and its congeners belong to a group of flavonolignans with strong biological activities. These compounds are potentially applicable in human medicine, e. g. due to their cytoprotective activity. As a part of herbal preparations available on the open market, they face the risk of potential negative drug-drug interactions. This review aims to evaluate current knowledge on the metabolism of these compounds by biotransformation enzymes, interactions with other drugs, their pharmacokinetics, and bioavailability. While silybin and its derivatives interact with cytochrome P450s, only metabolism of silybin by cytochrome P450 2C8 poses a risk of adverse effects. The main biotransformation route of silybin and derivatives was identified as conjugation, which is stereospecific in case of silybin. Studies of the metabolism, pharmacokinetics, potentional drug – drug interactions and increasing bioavailability of these flavonolignans play an important facet of possible therapeutical use of these compounds. The goal of our review is to aid future developments in the area of silybin research.
Export Options
About this article
Cite this article as:
Kren Vladimír, Marhol Petr, Purchartová Katerina, Gabrielová Eva and Modriansky Martin, Biotransformation of Silybin and its Congeners, Current Drug Metabolism 2013; 14 (10) . https://dx.doi.org/10.2174/1389200214666131118234507
DOI https://dx.doi.org/10.2174/1389200214666131118234507 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design Computational Methods and Algorithms for Mass Spectrometry Based Differential Proteomics: Recent Advances, Perspectives and Open Problems
Current Proteomics miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Applications of X-Ray Diffraction Imaging to Mammography
Recent Patents on Medical Imaging Subject Index To Volume 13
Current Medicinal Chemistry Quantum Dot-Based Nanocomposites for Biomedical Applications
Current Medicinal Chemistry Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Development of Microwave Antennas for Thermal Therapy
Current Pharmaceutical Design Chemotherapy in Addition to Preoperative Radiotherapy in Locally Advanced Rectal Cancer – A Systematic Overview
Reviews on Recent Clinical Trials Azelaic Acid: A Promising Agent for Dermatological Applications
Current Drug Therapy Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Sphingolipid Signaling Pathways as Potential Therapeutic Targets in Gliomas
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors)
Current Drug Targets